SRPT - Sarepta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
122.80
+1.48 (+1.22%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close121.32
Open122.46
Bid120.00 x 800
Ask123.80 x 900
Day's Range120.52 - 123.22
52 Week Range50.68 - 176.50
Volume587,319
Avg. Volume1,047,812
Market Cap8.659B
Beta (3Y Monthly)3.36
PE Ratio (TTM)N/A
EPS (TTM)-3.77
Earnings DateFeb 27, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est194.36
Trade prices are not sourced from all markets
  • 3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
    Motley Fool18 hours ago

    3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs

    Here's what you need to know about the FDA's latest plans to meet the biotech industry halfway.

  • Markit3 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    # Sarepta Therapeutics Inc ### NASDAQ/NGS:SRPT View full report here! ## Summary * Bearish sentiment is high and has been increasing ## Bearish sentiment Short interest | Negative Short interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. Sentiment has worsened and traders added to their bearish short positions on January 16. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $3.51 billion over the last one-month into ETFs that hold SRPT are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • CNBC5 days ago

    Here are top analysts' 5 favorite growth stocks for 2019

    Even in these uncertain times, there are still compelling growth stocks to be found. These are TipRanks' five picks.

  • Here’s your guide to the upcoming biotechnology takeover wave
    MarketWatch5 days ago

    Here’s your guide to the upcoming biotechnology takeover wave

    Biotechnology companies have been hit so hard, Big Pharma is now picking them off one by one in takeovers. This makes biotech companies look very attractive. In the weakness, for example, Celgene (CELG) hit its lowest price-to-earnings ratio in history, or around six.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    # Sarepta Therapeutics Inc ### NASDAQ/NGS:SRPT View full report here! ## Summary * Bearish sentiment is moderate and declining ## Bearish sentiment Short interest | Neutral Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 8. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $4.89 billion over the last one-month into ETFs that hold SRPT are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • FDA pilot program could help Wave avoid orphan-drug pitfalls
    American City Business Journals6 days ago

    FDA pilot program could help Wave avoid orphan-drug pitfalls

    Wave will work with FDA officials during the pilot program to design a Phase 2-3 clinical trial with a reduced number of placebo patients, tweaking standards that have stymied other rare disease products.

  • GlobeNewswire7 days ago

    Analysis: Positioning to Benefit within Alphabet, Globalstar, Ingevity, Vocera Communications, Sarepta Therapeutics, and FLIR — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Jan. 14, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • 3 Biotech Stocks to Watch in 2019
    Motley Fool9 days ago

    3 Biotech Stocks to Watch in 2019

    Clinical-trial and regulatory-review decisions make these three drug developers worth keeping tabs on this year.

  • InvestorPlace10 days ago

    Why Sarepta Therapeutics Stock Is Starting to Shine Again

    Sarepta Therapeutics (NASDAQ:SRPT) started 2019 with very high volatility. After spiking to around $125 a share on Jan. 7, SRPT stock gave up those gains when markets took in the developments in its DMD pipelines and its Exondys 51 fourth-quarter sales outlook. Although shares rebounded from December 2018 lows, should biotech stock investors seriously consider investing in this company? At the J.P. Morgan conference, Sarepta said it will run 45 biopsies this quarter for SRP-4045. This is an investigational compound that treats DMD or Duchenne muscular dystrophy patients with mutations in the DMD gene. The drug works by directing cells, through Sarepta's PMO, to skip exon 45 when processing RNA. The dystrophin protein is shortened but is still synthesized, slowing the negative symptoms of DMD. If the biopsies are positive, Sarepta will file a marketing application, setting up a possible approval date of early 2020. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### SRPT's Sales Outlook SRPT stock volatility rose after the company issued its revenue outlook for Exondys 51. In the fourth quarter ended Dec. 31, 2018, it made $84.4 million in revenue from sales of Exondys 51. For 2018, revenue was around $301 million. It ended that same period with a healthy balance of $1.1 billion in cash. * 10 Key Emerging-Market Stocks to Buy for Contrarian Investors Markets reacted negatively to the outlook because it expected quarterly revenue of $85.8 million. The barely $2 million difference is a rounding error and the market quickly realized it. Quarterly revenue is in line with forecasts. As markets rebounded, taking the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) up 11.5% on the week, SRPT stock also rose the same amount (11%). Sarepta's global growth plans should lower the risks of relying solely in one market: "We continue to build our international presence with limited infrastructure but dedicated colleagues in Latin America and Europe and a managed access program or MAP now live in some 44 countries. We should continue to see modest contribution from our MAP throughout 2018 with increasing contribution in 2019 and beyond." Source: SA Transcript ### Impressive Talent at Sarepta Sarepta highlighted the 25 programs in RNA and gene therapy underway. Its staff talent consists of over 500 professionals. This leading gene therapy team could deliver on bringing 3 RNA-therapies by 2020. It may potentially treat 30% of the DMD market. Historically, the team is showing that it is delivering. FY 2018 revenue nearly doubled to $301 million, up from the 2017 revenue of $154.6 million. ### Investing Opportunity Sarepta is a top five rare disease company by market cap. Only Alexion Pharmaceuticals (NASDAQ:ALXN), BioMarin Pharmaceutical (NASDAQ:BMRN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are bigger. SRPT stock is underperforming compared to its peers. While the other firms' stock price traded closer to its 52-week highs after the market rally in the last few days, Sarepta is still around 33% below its yearly high. Wall Street coverage gained steam in the last few days. The company received over five "buy" calls, with a price target ranging from $161 to as high as $267. Analyst Firm Position Price Target Date Debjit Chattopadhyay H.C. Wainwright Buy $267.00 yesterday Salveen Richter Goldman Sachs Buy $191.00 2 days ago Matthew Harrison Morgan Stanley Buy $161.00 2 days ago Brian Skorney Robert W. Baird Buy $202.00 2 days ago Alethia Young Cantor Fitzgerald Buy $217.00 2 days ago Yun Zhong Janney Montgomery Buy $200.00 2 days ago Brian Abrahams RBC Capital Buy -- 3 days ago Martin Auster Credit Suisse Buy $189.00 3 days ago Tim Chiang BTIG Buy $190.00 13 days ago Source: tipranks ### Investment Suitability Like with all biotech companies in the discovery phase, SRPT is volatile and risky. Any FDA approval delays could disappoint markets, sending the stock lower. Clinical study costs could rise, but in Sarepta's case, the company has plenty of cash on hand. It is unlikely to need a cash raise through a share sale. * 7 Stocks to Buy That Are Run By Billionaires ### Bottom Line on SRPT Stock Sarepta Therapeutics stock benefited from the latest rebound in biotechnology stocks, but could move even higher in the longer term. It has a goal of commencing its confirmatory trial with commercial material this year. Given the strong team, doctors and scientists involved, chances are good that the trial, which has 24 patients, goes well and will bring positive results. As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post Why Sarepta Therapeutics Stock Is Starting to Shine Again appeared first on InvestorPlace.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    # Sarepta Therapeutics Inc ### NASDAQ/NGS:SRPT View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining ## Bearish sentiment Short interest | Neutral Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 8. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding SRPT is favorable, with net inflows of $8.77 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Benzinga13 days ago

    Janney, Morgan Stanley Say Sarepta's Gene Therapy Remains On Track

    Sarepta Therapeutics Inc  (NASDAQ:  SRPT ) shares were under pressure this week following a regulatory update that analysts say may have been misunderstood by the market.  Sarepta shares were down 5 percent ...

  • 4 Biotechs That Are Potential Buyouts Post Celgene Deal
    Zacks13 days ago

    4 Biotechs That Are Potential Buyouts Post Celgene Deal

    We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.

  • A Look at Sarepta Therapeutics’ Recent Developments
    Market Realist13 days ago

    A Look at Sarepta Therapeutics’ Recent Developments

    Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Earnings trends In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year. In the third quarter of 2018, the company reported net income and EPS of -$76.4 million and -$1.15, respectively, compared to -$47.7 million and -$0.78 in the third quarter of 2017. Wall Street analysts anticipate that in the fourth quarter of 2018, Sarepta Therapeutics will report net income and EPS of -$63.26 million and -$0.95, respectively. Analysts also estimate that the company will report net income and EPS of -$274.73 million and -$4.16, respectively, in fiscal 2018. Wall Street analysts estimate that BioMarin Pharmaceuticals (BMRN), Nektar Therapeutics (NKTR), and Vertex Pharmaceuticals (VRTX), Sarepta Therapeutics’ peers in the biopharmaceuticals market, will report EPS of around -$0.62, $3.88, and $2.88, respectively, in fiscal 2018. ## Recent developments On January 2, 2019, Sarepta Therapeutics entered a long-term strategic relationship with Aldevron. Aldevron is one of the leading producers of custom proteins, nucleic acids, and antibodies for use in the biotech industry. As per the terms of the agreement, Aldevron will supply plasmid DNA for the fulfillment of Sarepta Therapeutics’ requirements in its gene therapy clinical trials and commercial purposes. Aldevron will specifically supply GMP-grade plasmid for Sarepta Therapeutics’ micro-dystrophin Duchenne muscular dystrophy (or DMD) and Limb-girdle muscular dystrophy (or LGMD) gene therapy programs. As per the terms of the agreement, Aldevron will also supply plasmid for Sarepta Therapeutics’ future gene therapy programs. The agreement is expected to help Sarepta Therapeutics with sufficient plasmid for research and commercial purposes. Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 2 - How Is Sarepta Therapeutics Positioned in January?

  • How Is Sarepta Therapeutics Positioned in January?
    Market Realist14 days ago

    How Is Sarepta Therapeutics Positioned in January?

    Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million. In the third quarter of 2018, the company’s revenue grew ~71% YoY to $78.5 million from $46.0 million. Wall Street analysts estimate that Sarepta Therapeutics will generate revenues of $85.8 million in the fourth quarter of 2018. Analysts also estimate that the company’s net revenue in fiscal 2018 will be around $301.1 million, which represents ~49.9% YoY growth. In the third quarter of 2018, Nektar Therapeutics (NKTR), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN), Sarepta Therapeutics’ peers in the biopharmaceuticals market, reported revenues of $27.8 million, $783.9 million, and $391.7 million, respectively, which represents a ~81.9% YoY decline, a ~42.04% YoY increase, and a ~17.23% YoY increase. Wall Street analysts estimate that Nektar Therapeutics (NKTR), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN) will generate revenues of $1.2 billion, $3.0 billion, and $1.5 billion, respectively, which represents ~289%, ~37.41%, and ~15% YoY growth. ## Expense trends In the first nine months of 2018, Sarepta Therapeutics’ cost of sales excluding amortization of in-licensed rights amounted to $21.1 million compared to $3.8 million in the same period the prior year. In the first nine months of 2018, Sarepta Therapeutics reported R&D (research and development) and SG&A (selling, general, and administrative) expenses of $255.6 million and $143.5 million, respectively, compared to $122.3 million and $90.5 million in the same period the prior year. Wall Street analysts estimate that Sarepta Therapeutics will report cost of sales, SG&A, and R&D expenses of $30.2 million, $190.88 million and $317.02 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 3 - A Look at Sarepta Therapeutics’ Recent Developments

  • Sarepta Therapeutics Stock Rose 96% in 2018
    Market Realist14 days ago

    Sarepta Therapeutics Stock Rose 96% in 2018

    Who Is Eyeing Sarepta Therapeutics Now? ## Stock performance On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its close of $106.67 on January 3. Sarepta Therapeutics stock grew from $55.64 at the close of market on December 29, 2017, to reach $109.13 at the close of market on December 31, 2018, which represents ~96% growth over 2018. On January 2, 2019, Sarepta Therapeutics stock closed at $107.50, which is ~35% below its 52-week high of $176.50 on June 19, 2018. The company hit its 52-week low of $26.26 on February 13, 2018. ## Recent developments In December 2018, Sarepta Therapeutics (SRPT) completed the submission of its continuing NDA (new drug application) that seeks approval of its golodirsen for the treatment of individuals with Duchenne muscular dystrophy with genetic mutations associated to skipping exon 53 Duchenne gene. Sarepta Therapeutics’ golodirsen is an engineered phosphorodiamidate morpholino oligomer for the treatment of DMD with genetic mutations of skipping exon 53 of the DMD gene. ## Analyst recommendations Of the 24 analysts tracking Sarepta Therapeutics in January 2019, nine of them recommended a “strong buy,” while 14 analysts recommended a “buy” rating. One analyst recommended a “hold” for Sarepta Therapeutics in January. On January 7, Sarepta Therapeutics had a consensus 12-month target price of $194.36, which represents a ~68.38% return on investment over the next 12-months. ## Peers’ ratings In January 2018, of 27 analysts tracking BioMarin Pharmaceuticals (BMRN), ~78% of them recommended “buys.” Of the 11 analysts tracking Exelixis (EXEL), ~73% of them recommended “buys.” Of the 11 analysts tracking Nektar Therapeutics (NKTR), ~82% of them recommended “buys.” On January 7, BioMarin Pharmaceuticals (BMRN), Exelixis (EXEL), and Nektar Therapeutics (NKTR) had a consensus 12-month target price of $120.3, $28.78, and $78.89, respectively, which represents ~38.12%, ~38.83%, and a ~132.30% return on investment over the next 12 months. Continue to Next Part Browse this series on Market Realist: * Part 2 - How Is Sarepta Therapeutics Positioned in January? * Part 3 - A Look at Sarepta Therapeutics’ Recent Developments

  • Here's Why Sarepta Therapeutics Fell 15.7% in December
    Motley Fool17 days ago

    Here's Why Sarepta Therapeutics Fell 15.7% in December

    A competitive threat is advancing, but investors might want to view last month's pullback as an opportunity.

  • Markit17 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    Short interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. Over the last month, growth of ETFs holding SRPT is favorable, with net inflows of $9.76 billion.

  • Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply
    Zacks18 days ago

    Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply

    Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.

  • GlobeNewswire19 days ago

    Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy

    -- Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy.

  • GlobeNewswire19 days ago

    Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Sarepta Therapeutics, Inc. (SRPT), a leader in precision genetic medicine for rare diseases, today announced that management will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 7th at 10:30 a.m. ET / 7:30 a.m. PT. Following the presentation there will be a Q&A session starting at 11:00 a.m. ET / 8:00 a.m. PT. The presentation and Q&A session will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation and Q&A session for 90 days.

  • GlobeNewswire20 days ago

    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Sarepta Therapeutics, Inc. (SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to twenty-three individuals hired by Sarepta in December 2018. The employees received, in the aggregate, options to purchase 40,950 shares of Sarepta's common stock, and in the aggregate, 13,500 restricted stock units (“RSUs”). The options have an exercise price of $109.13 per share, which is equal to the closing price of Sarepta's common stock on December 31, 2018 (the “Grant Date”).

  • See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
    Markit21 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan. Over the last month, growth of ETFs holding SRPT is favorable, with net inflows of $8.55 billion. Index (PMI) data, output in the Healthcare sector is rising.

  • Biotech Buying Spree: Why These 3 Stocks Could Get Deals In 2019
    Investor's Business Daily28 days ago

    Biotech Buying Spree: Why These 3 Stocks Could Get Deals In 2019

    Sarepta Therapeutics, Sage Therapeutics and Loxo Oncology are the most likely takeover candidates among biotech stocks in 2019, according to a survey from RBC Capital Markets analysts.

  • Do Analysts See Any Upside for Sarepta Stock?
    Market Realistlast month

    Do Analysts See Any Upside for Sarepta Stock?

    Of the 23 analysts covering Sarepta Therapeutics (SRPT), 22 have given it “buy” or higher ratings, and one has given it a “hold.”

  • Understanding Sarepta Therapeutics’ Operational Performance
    Market Realistlast month

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million from $34.24 million due to higher clinical and manufacturing expenses resulting from increased patient enrolment in the Essence trial, increased up-front and license payments, and higher compensation expenses.